Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, discusses adeno-associated virus (AAV) gene therapies for the treatment of hemophilia A and hemophilia B. Dr Coppens describes how these treatments have allowed many patients to discontinue prophylaxis and shares some of the differences observed between patients with hemophilia A and those with hemophilia B. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.